MX2017009044A - Metodo para el tratamiento de malignidades. - Google Patents
Metodo para el tratamiento de malignidades.Info
- Publication number
- MX2017009044A MX2017009044A MX2017009044A MX2017009044A MX2017009044A MX 2017009044 A MX2017009044 A MX 2017009044A MX 2017009044 A MX2017009044 A MX 2017009044A MX 2017009044 A MX2017009044 A MX 2017009044A MX 2017009044 A MX2017009044 A MX 2017009044A
- Authority
- MX
- Mexico
- Prior art keywords
- provides
- malignancies
- treatment
- electroporation
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención hace posible el suministro intratumoral de inmunomoduladores. En particular, proporciona el suministro de moléculas coestimuladoras al utilizar electroporación intratumoral.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562101850P | 2015-01-09 | 2015-01-09 | |
US201562126300P | 2015-02-27 | 2015-02-27 | |
PCT/US2016/012759 WO2016112359A1 (en) | 2015-01-09 | 2016-01-08 | Method for the treatment of malignancies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017009044A true MX2017009044A (es) | 2018-01-11 |
Family
ID=56356515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017009044A MX2017009044A (es) | 2015-01-09 | 2016-01-08 | Metodo para el tratamiento de malignidades. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20180000895A1 (es) |
EP (2) | EP3799879A1 (es) |
JP (3) | JP2018504403A (es) |
CA (1) | CA2973390A1 (es) |
DK (1) | DK3242947T3 (es) |
ES (1) | ES2809734T3 (es) |
MX (1) | MX2017009044A (es) |
PL (1) | PL3242947T3 (es) |
WO (1) | WO2016112359A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
JP2021508533A (ja) | 2017-12-26 | 2021-03-11 | ギャラリー,インコーポレイテッド | 様々な用途のためのエネルギー送達の最適化 |
SG11202010395XA (en) * | 2018-05-02 | 2020-11-27 | Oncosec Medical Inc | Electroporation systems, methods, and apparatus |
EP3833323A4 (en) * | 2018-08-08 | 2022-08-10 | Cedars-Sinai Medical Center | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES |
CA3149494A1 (en) | 2019-08-12 | 2021-02-18 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells |
WO2021074695A1 (en) | 2019-10-16 | 2021-04-22 | Avacta Life Sciences Limited | PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES. |
GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
WO2023057946A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Serum half-life extended pd-l1 binding polypeptides |
TW202334196A (zh) | 2021-10-07 | 2023-09-01 | 英商阿法克塔生命科學有限公司 | Pd-l1結合多肽 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5993434A (en) * | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
US20030049696A1 (en) | 2001-06-07 | 2003-03-13 | Norment Anne M. | Regulatory T cells and uses thereof |
US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
US20110142887A1 (en) * | 2009-12-15 | 2011-06-16 | Immunovative Therapies Ltd. | Methods and compositions for liquidation of tumors |
CA3031833C (en) | 2003-05-30 | 2022-07-26 | University Of South Florida | Uses of il-2 as a therapeutic medicament in combination with electroporation for the treatment of malignancies |
US8802643B1 (en) * | 2003-05-30 | 2014-08-12 | University Of South Florida | Method for the treatment of malignancies |
US7923251B2 (en) | 2005-02-23 | 2011-04-12 | The Board Of Trustees Of The Leland Stanford Junior University | Method and apparatus for avalanche-mediated transfer of agents into cells |
US8101169B2 (en) | 2005-02-23 | 2012-01-24 | The Board Of Trustees Of The Leland Stanford Junior University | Ocular gene therapy using avalanche-mediated transfection |
US20090081157A1 (en) * | 2006-01-09 | 2009-03-26 | Richard Syd Kornbluth | Immunostimulatory Combinations for Vaccine Adjuvants |
JPWO2010030002A1 (ja) * | 2008-09-12 | 2012-02-02 | 国立大学法人三重大学 | 外来性gitrリガンド発現細胞 |
MX354986B (es) * | 2011-12-12 | 2018-03-28 | Univ Pennsylvania | Composiciones que comprenden construcciones geneticas y vacunas de il-12 mejoradas, agentes inmunoterapeuticos y metodos para su uso. |
-
2016
- 2016-01-08 EP EP20176001.4A patent/EP3799879A1/en active Pending
- 2016-01-08 PL PL16735524T patent/PL3242947T3/pl unknown
- 2016-01-08 EP EP16735524.7A patent/EP3242947B1/en active Active
- 2016-01-08 MX MX2017009044A patent/MX2017009044A/es unknown
- 2016-01-08 CA CA2973390A patent/CA2973390A1/en active Pending
- 2016-01-08 DK DK16735524.7T patent/DK3242947T3/da active
- 2016-01-08 ES ES16735524T patent/ES2809734T3/es active Active
- 2016-01-08 WO PCT/US2016/012759 patent/WO2016112359A1/en active Application Filing
- 2016-01-08 JP JP2017536882A patent/JP2018504403A/ja active Pending
- 2016-01-08 US US15/542,415 patent/US20180000895A1/en not_active Abandoned
-
2020
- 2020-09-29 JP JP2020164124A patent/JP7111384B2/ja active Active
-
2022
- 2022-07-13 JP JP2022112196A patent/JP2022137203A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3242947A1 (en) | 2017-11-15 |
JP7111384B2 (ja) | 2022-08-02 |
EP3242947B1 (en) | 2020-05-27 |
CA2973390A1 (en) | 2016-07-14 |
ES2809734T3 (es) | 2021-03-05 |
US20180000895A1 (en) | 2018-01-04 |
JP2018504403A (ja) | 2018-02-15 |
EP3799879A1 (en) | 2021-04-07 |
EP3242947A4 (en) | 2018-08-08 |
WO2016112359A1 (en) | 2016-07-14 |
DK3242947T3 (da) | 2020-08-03 |
PL3242947T3 (pl) | 2021-01-11 |
JP2021008481A (ja) | 2021-01-28 |
JP2022137203A (ja) | 2022-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017009044A (es) | Metodo para el tratamiento de malignidades. | |
CY1121348T1 (el) | Mrna θεραπεια για την θεραπευτικη αγωγη οφθαλμικων ασθενειων | |
MX2020003939A (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos. | |
MX2020010694A (es) | Particulas de raav que codifican mir-708 y usos del mismo. | |
MX2020011783A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
MX2022004786A (es) | Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular. | |
JO3556B1 (ar) | علاجات مدمجة لمعالجة السرطان | |
EP4309643A3 (en) | Viscosity-reducing excipient compounds for protein formulations | |
MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
MX2017004510A (es) | Triazolopirazinonas como inhibidores de pde1. | |
MX2018001511A (es) | Polimeros furtivos desordenados de forma intrinseca codificados geneticamente para suministro y metodos para usar los mismos. | |
PH12017501990A1 (en) | Imidazopyrazinones as pde1 inhibitors | |
MX2016011862A (es) | Inhibidores de c5a para el tratamiento de la neumonia viral. | |
EA201591924A1 (ru) | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 | |
EP3998341A3 (en) | Adenoviral vectors | |
MX2018015110A (es) | Arn modificado que codifica polipeptidos de vegf-a. formulaciones y usos relacionados con los mismos. | |
MX2020003385A (es) | Vectores adenovirales de replicacion competente. | |
MX2019013124A (es) | Proteinas de fusion de inhibidor de tripsina urinaria (uti). | |
MX2019006552A (es) | Terapia génica para mucopolisacaridosis de tipo i. | |
MX2023007706A (es) | Nanoparticulas para su uso como vacuna terapeutica. | |
WO2018081817A3 (en) | Targeting microrna-101-3p in cancer therapy | |
PH12016501495A1 (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
MA40642A (fr) | Nouveaux dérivés peptidiques et leurs utilisations | |
WO2015168102A3 (en) | Prolonged protein stabilization by resveratrol |